{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:15:53Z","timestamp":1782306953729,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA246409-01"],"award-info":[{"award-number":["R21CA246409-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["F32HL168948"],"award-info":[{"award-number":["F32HL168948"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","award":["S10OD030447"],"award-info":[{"award-number":["S10OD030447"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Treatment of pediatric cancers with doxorubicin is a common and predictable cause of cardiomyopathy. Early diagnosis of treatment-induced cardiotoxicity and intervention are major determinants for the prevention of advanced disease. The onset of cardiomyopathies is often accompanied by profound changes in lipid metabolism, including an enhanced uptake of short-chain fatty acids (SCFA). Therefore, we explored the utility of 2-[\n                      <jats:sup>18<\/jats:sup>\n                      F]fluoropropionic acid ([\n                      <jats:sup>18<\/jats:sup>\n                      F]FPA), an SCFA analog, as an imaging biomarker of cardiac injury in mice exposed to doxorubicin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedures<\/jats:title>\n                    <jats:p>\n                      Cardiotoxicity and cardiac dysfunction were induced in mice by an 8-dose regimen of doxorubicin (cumulative dose 24\u00a0mg\/kg) administered over 14\u00a0days. The effects of doxorubicin exposure were assessed by measurement of heart weights, left ventricular ejection fractions, and blood cardiac troponin levels. Whole body and cardiac [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPA uptakes were determined by PET and tissue gamma counting in the presence or absence of AZD3965, a pharmacological inhibitor of monocarboxylate transporter 1 (MCT1). Radiation absorbed doses were estimated using tissue time-activity concentrations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significantly higher cardiac [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPA uptake was observed in doxorubicin-treated animals. This uptake remained constant from 30 to 120\u00a0min post-injection. Pharmacological inhibition of MCT1-mediated transport by AZD3965 selectively decreased the uptake of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPA in tissues other than the heart. Co-administration of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPA and AZD3965 enhanced the imaging contrast of the diseased heart while reducing overall exposure to radioactivity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]FPA, especially when co-administered with AZD3965, is a new tool for imaging changes in fatty acid metabolism occurring in response to doxorubicin-induced cardiomyopathy by PET.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11307-024-01978-y","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T12:37:10Z","timestamp":1736858230000},"page":"109-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["2-[18F]Fluoropropionic Acid PET Imaging of Doxorubicin-Induced Cardiotoxicity"],"prefix":"10.1007","volume":"27","author":[{"given":"Juan A.","family":"Azcona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja S.","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul-Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward K.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Jeitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onorina L.","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Di Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Babich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Amor-Coarasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-0047","authenticated-orcid":false,"given":"James M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"8","key":"1978_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J (2020) Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 17(8):474\u2013502","journal-title":"Nat Rev Cardiol"},{"key":"1978_CR2","doi-asserted-by":"publisher","first-page":"3579143","DOI":"10.1155\/2020\/3579143","volume":"2020","author":"Z Ping","year":"2020","unstructured":"Ping Z, Peng Y, Lang H et al (2020) Oxidative stress in radiation-induced cardiotoxicity. Oxid Med Cell Longev 2020:3579143","journal-title":"Oxid Med Cell Longev"},{"key":"1978_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-43032-0_15","volume":"1257","author":"A Bhagat","year":"2020","unstructured":"Bhagat A, Kleinerman ES (2020) Anthracycline-induced cardiotoxicity: causes, mechanisms, and prevention. Adv Exp Med Biol 1257:181\u2013192","journal-title":"Adv Exp Med Biol"},{"key":"1978_CR4","doi-asserted-by":"publisher","first-page":"111708","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U (2021) Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother 139:111708","journal-title":"Biomed Pharmacother"},{"issue":"2\u20133","key":"1978_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.tox.2010.01.019","volume":"270","author":"RA Carvalho","year":"2010","unstructured":"Carvalho RA, Sousa RPB, Cadete VJJ et al (2010) Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology 270(2\u20133):92\u201398","journal-title":"Toxicology"},{"issue":"3","key":"1978_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1161\/hc0302.102594","volume":"105","author":"ED Lewandowski","year":"2002","unstructured":"Lewandowski ED, Kudej RK, White LT, O\u2019Donnell JM, Vatner SF (2002) Mitochondrial preference for short chain fatty acid oxidation during coronary artery constriction. Circulation 105(3):367\u2013372","journal-title":"Circulation"},{"key":"1978_CR7","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1161\/CIRCULATIONAHA.120.052671","volume":"143","author":"AN Carley","year":"2021","unstructured":"Carley AN, Maurya SK, Fasano M et al (2021) Short-chain fatty acids outpace ketone oxidation in the failing heart. Circulation 143:1797\u20131808","journal-title":"Circulation"},{"key":"1978_CR8","doi-asserted-by":"publisher","first-page":"915102","DOI":"10.3389\/fcvm.2022.915102","volume":"9","author":"CL Palm","year":"2022","unstructured":"Palm CL, Nijholt KT, Bakker BM, Westenbrink BD (2022) Short-chain fatty acids in the metabolism of heart failure \u2013 rethinking the fat stigma. Front Cardiovasc Med 9:915102","journal-title":"Front Cardiovasc Med"},{"issue":"6","key":"1978_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1194\/jlr.R067629","volume":"57","author":"P Sch\u00f6nfeld","year":"2016","unstructured":"Sch\u00f6nfeld P, Wojtczak L (2016) Short- and medium-chain fatty acids in energy metabolism: the cellular perspective. J Lipid Res 57(6):943","journal-title":"J Lipid Res"},{"issue":"10","key":"1978_CR10","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2967\/jnumed.109.064212","volume":"50","author":"NVK Pillarsetty","year":"2009","unstructured":"Pillarsetty NVK, Punzalan B, Larson SM (2009) 2\u201318F-Fluoropropionic acid as a PET imaging agent for prostate cancer. J Nucl Med 50(10):1709\u20131714","journal-title":"J Nucl Med"},{"issue":"6","key":"1978_CR11","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s11307-019-01346-1","volume":"21","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Liu S, Ma H et al (2019) Validation of R-2-[18F]Fluoropropionic acid as a potential tracer for PET imaging of liver cancer. Mol imaging Biol 21(6):1127\u20131137","journal-title":"Mol imaging Biol"},{"key":"1978_CR12","doi-asserted-by":"publisher","first-page":"153601211882103","DOI":"10.1177\/1536012118821032","volume":"18","author":"J Zhao","year":"2019","unstructured":"Zhao J, Zhang Z, Nie D et al (2019) PET imaging of hepatocellular carcinomas: 18F-Fluoropropionic acid as a complementary radiotracer for 18F-Fluorodeoxyglucose. Mol Imaging 18:1536012118821032","journal-title":"Mol Imaging"},{"issue":"1","key":"1978_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10967-018-5753-0","volume":"316","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Liu S, Tang X et al (2018) Radiosynthesis and preliminary biological evaluation of the 2-[18F]fluoropropionic acid enantiomers for tumor PET imaging. J Radioanal Nucl Chem 316(1):153\u2013159","journal-title":"J Radioanal Nucl Chem"},{"issue":"6","key":"1978_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s11307-021-01608-x","volume":"23","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Liu S, Ma H et al (2021) Propionic acid-based PET imaging of prostate cancer. Mol Imaging Biol 23(6):836\u2013845","journal-title":"Mol Imaging Biol"},{"key":"1978_CR15","doi-asserted-by":"publisher","first-page":"216329","DOI":"10.1016\/j.canlet.2023.216329","volume":"570","author":"M De Martino","year":"2023","unstructured":"De Martino M, Daviaud C, Minns HE et al (2023) Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma. Cancer Lett 570:216329","journal-title":"Cancer Lett"},{"issue":"1","key":"1978_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2967\/jnmt.113.132621","volume":"42","author":"DS Surasi","year":"2014","unstructured":"Surasi DS, Bhambhvani P, Baldwin JA, Almodovar SE, O\u2019Malley JP (2014) 18F-FDG PET and PET\/CT patient preparation: a review of the literature. J Nucl Med Technol 42(1):5\u201313","journal-title":"J Nucl Med Technol"},{"issue":"4","key":"1978_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2967\/jnumed.119.233288","volume":"61","author":"S Srinivasan","year":"2020","unstructured":"Srinivasan S, Crandall JP, Gajwani P et al (2020) Human radiation dosimetry for orally and intravenously administered 18F-FDG. J Nucl Med 61(4):613\u2013619","journal-title":"J Nucl Med"},{"issue":"1","key":"1978_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-018-0462-9","volume":"8","author":"S Gnesin","year":"2018","unstructured":"Gnesin S, Cicone F, Mitsakis P et al (2018) First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist 68 Ga-NODAGA-MJ9. EJNMMI Res 8(1):1\u201310","journal-title":"EJNMMI Res"},{"key":"1978_CR19","first-page":"17","volume":"10","author":"MA Mitry","year":"2016","unstructured":"Mitry MA, Edwards JG (2016) Doxorubicin induced heart failure: Phenotype and molecular mechanisms. IJC Hear Vasc 10:17\u201324","journal-title":"IJC Hear Vasc"},{"key":"1978_CR20","doi-asserted-by":"publisher","first-page":"670479","DOI":"10.3389\/fphar.2021.670479","volume":"12","author":"EY Podyacheva","year":"2021","unstructured":"Podyacheva EY, Kushnareva EA, Karpov AA, Toropova YG (2021) Analysis of models of doxorubicin-induced cardiomyopathy in rats and mice. A modern view from the perspective of the pathophysiologist and the clinician. Front Pharmacol 12:670479","journal-title":"Front Pharmacol"},{"issue":"1","key":"1978_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12094-016-1508-y","volume":"19","author":"J Gavila","year":"2017","unstructured":"Gavila J, Segu\u00ed M, Calvo L et al (2017) Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study. Clin Transl Oncol 19(1):91\u2013104","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"1978_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/0005-2760(75)90040-5","volume":"380","author":"PH Groot","year":"1975","unstructured":"Groot PH (1975) The activation of short-chain fatty acids by the soluble fraction of guinea-pig heart and liver mitochondria. The search for a distinct propionyl-CoA synthetase. Biochim Biophys Acta 380(1):12\u201320","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1978_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ygeno.2009.03.003","volume":"94","author":"D Colak","year":"2009","unstructured":"Colak D, Kaya N, Al-Zahrani J et al (2009) Left ventricular global transcriptional profiling in human end-stage dilated cardiomyopathy. Genomics 94(1):20","journal-title":"Genomics"},{"issue":"5","key":"1978_CR24","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s12350-018-1458-6","volume":"27","author":"AH Laursen","year":"2020","unstructured":"Laursen AH, Elming MB, Ripa RS et al (2020) Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. J Nucl Cardiol 27(5):1698\u20131707","journal-title":"J Nucl Cardiol"},{"key":"1978_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.clinimag.2020.07.026","volume":"68","author":"SA Nehmeh","year":"2020","unstructured":"Nehmeh SA, Fox JJ, Schwartz J et al (2020) A pilot study of 13N-ammonia cardiac PET imaging to assess subacute cardiotoxicity following adjuvant intensity-modulated radiotherapy for locally advanced breast cancer. Clin Imaging 68:283\u2013290","journal-title":"Clin Imaging"},{"issue":"2","key":"1978_CR26","doi-asserted-by":"publisher","first-page":"E014419","DOI":"10.1161\/CIRCIMAGING.122.014419","volume":"16","author":"N Marzlin","year":"2023","unstructured":"Marzlin N, Hays AG, Peters M et al (2023) Myocardial work in echocardiography. Circ Cardiovasc Imaging 16(2):E014419","journal-title":"Circ Cardiovasc Imaging"},{"key":"1978_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejmp.2020.01.008","volume":"70","author":"F Santini","year":"2020","unstructured":"Santini F, Gui L, Lorton O et al (2020) Ultrasound-driven cardiac MRI. Phys Medica 70:161\u2013168","journal-title":"Phys Medica"},{"issue":"12","key":"1978_CR28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00259-002-0979-y","volume":"29","author":"TO Takala","year":"2002","unstructured":"Takala TO, Nuutila P, Pulkki K et al (2002) 14(R, S)-[18F]Fluoro-6-thia-heptadecanoic acid as a tracer of free fatty acid uptake and oxidation in myocardium and skeletal muscle. Eur J Nucl Med 29(12):1617\u20131622","journal-title":"Eur J Nucl Med"},{"issue":"4","key":"1978_CR29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/01.CIR.80.4.863","volume":"80","author":"JJ Armbrecht","year":"1989","unstructured":"Armbrecht JJ, Buxton DB, Brunken RC, Phelps ME, Schelbert HR (1989) Regional myocardial oxygen consumption determined noninvasively in humans with [1-11C]acetate and dynamic positron tomography. Circulation 80(4):863\u2013872","journal-title":"Circulation"},{"issue":"12","key":"1978_CR30","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.2967\/jnumed.107.044503","volume":"48","author":"P Herrero","year":"2007","unstructured":"Herrero P, Dence CS, Coggan AR, Kisrieva-Ware Z, Eisenbeis P, Gropler RJ (2007) L-3-11C-lactate as a PET tracer of myocardial lactate metabolism: a feasibility study. J Nucl Med 48(12):2046\u20132055","journal-title":"J Nucl Med"},{"issue":"6","key":"1978_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1161\/01.CIR.55.6.853","volume":"55","author":"BE Sobel","year":"1977","unstructured":"Sobel BE, Weiss ES, Welch MJ, Siegel BA, Ter-Pogossian MM (1977) Detection of remote myocardial infarction in patients with positron emission transaxial tomography and intravenous 11C-palmitate. Circulation 55(6):853\u2013857","journal-title":"Circulation"},{"issue":"5","key":"1978_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","volume":"21","author":"CD Kemp","year":"2012","unstructured":"Kemp CD, Conte JV (2012) The pathophysiology of heart failure. Cardiovasc Pathol 21(5):365\u2013371","journal-title":"Cardiovasc Pathol"},{"issue":"6","key":"1978_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","volume":"113","author":"T Doenst","year":"2013","unstructured":"Doenst T, Nguyen TD, Abel ED (2013) Cardiac metabolism in heart failure. Circ Res 113(6):709\u2013724","journal-title":"Circ Res"},{"issue":"1122","key":"1978_CR34","doi-asserted-by":"publisher","first-page":"20201204","DOI":"10.1259\/bjr.20201204","volume":"94","author":"VS Krishnaraju","year":"2021","unstructured":"Krishnaraju VS, Singh H, Kumar R, Sharma S, Mittal BR, Bhattacharya A (2021) Infection imaging using [18F]FDG-labelled white blood cell positron emission tomography\u2013computed tomography. Br J Radiol 94(1122):20201204","journal-title":"Br J Radiol"},{"issue":"11","key":"1978_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12410-019-9517-1","volume":"12","author":"M Bauckneht","year":"2019","unstructured":"Bauckneht M, Cossu V, Miceli A et al (2019) FDG-PET Imaging of Doxorubicin-Induced Cardiotoxicity: a New Window on an Old Problem. Curr Cardiovasc Imaging Rep 12(11):1\u20138","journal-title":"Curr Cardiovasc Imaging Rep"},{"issue":"10","key":"1978_CR36","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1136\/gut.28.10.1221","volume":"28","author":"JH Cummings","year":"1987","unstructured":"Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT (1987) Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28(10):1221\u20131227","journal-title":"Gut"},{"issue":"12","key":"1978_CR37","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1158\/1535-7163.MCT-13-1091","volume":"13","author":"BM Bola","year":"2014","unstructured":"Bola BM, Chadwick AL, Michopoulos F et al (2014) Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther 13(12):2805\u20132816","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1978_CR38","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford S, Veal GJ, Wedge SR et al (2023) A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res 29(8):1429\u20131439","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1978_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-019-2735-z","volume":"37","author":"X Guan","year":"2020","unstructured":"Guan X, Morris ME (2020) Pharmacokinetics of the monocarboxylate transporter 1 inhibitor AZD3965 in mice: potential enterohepatic circulation and target-mediated disposition. Pharm Res 37(1):1\u201313","journal-title":"Pharm Res"},{"key":"1978_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-nutr-071813-105541","volume":"34","author":"TJ Grevengoed","year":"2014","unstructured":"Grevengoed TJ, Klett EL, Coleman RA (2014) Acyl-CoA metabolism and partitioning. Annu Rev Nutr 34:1","journal-title":"Annu Rev Nutr"},{"issue":"6","key":"1978_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.18632\/aging.100339","volume":"3","author":"MD Hirschey","year":"2011","unstructured":"Hirschey MD, Shimazu T, Capra JA, Pollard KS, Verdin E (2011) SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and HMGCS1,2. Aging (Albany NY) 3(6):635","journal-title":"Aging (Albany NY)"},{"issue":"9","key":"1978_CR42","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","volume":"64","author":"P Vejpongsa","year":"2014","unstructured":"Vejpongsa P, Yeh ETH (2014) Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 64(9):938\u2013945","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1978_CR43","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1194\/jlr.R036012","volume":"54","author":"G Den Besten","year":"2013","unstructured":"Den Besten G, Van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BB (2013) The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res 54(9):2325\u20132340","journal-title":"J Lipid Res"},{"issue":"22","key":"1978_CR44","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1158\/0008-5472.CAN-15-3034","volume":"76","author":"L Wang","year":"2016","unstructured":"Wang L, Chen Q, Qi H et al (2016) Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage. Cancer Res 76(22):6631\u20136642","journal-title":"Cancer Res"},{"issue":"3","key":"1978_CR45","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0306-4522(00)00294-3","volume":"100","author":"K Pierre","year":"2000","unstructured":"Pierre K, Pellerin L, Debernardi R, Riederer BM, Magistretti PJ (2000) Cell-specific localization of monocarboxylate transporters, MCT1 and MCT2, in the adult mouse brain revealed by double immunohistochemical labeling and confocal microscopy. Neuroscience 100(3):617\u2013627","journal-title":"Neuroscience"},{"key":"1978_CR46","doi-asserted-by":"crossref","unstructured":"Cardoso CV, de Barros MP, Bachi AL et al (2020) Chemobrain in rats: behavioral, morphological, oxidative and inflammatory effects of doxorubicin administration. Behav Brain Res 378:112233","DOI":"10.1016\/j.bbr.2019.112233"},{"issue":"10","key":"1978_CR47","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/j.bbamcr.2016.03.013","volume":"1863","author":"J P\u00e9rez-Escuredo","year":"2016","unstructured":"P\u00e9rez-Escuredo J, Van H\u00e9e VF, Sboarina M et al (2016) Monocarboxylate transporters in the brain and in cancer. Biochim Biophys Acta 1863(10):2481","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"1978_CR48","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00005768-200004000-00010","volume":"32","author":"A Bonen","year":"2000","unstructured":"Bonen A (2000) Lactate transporters (MCT proteins) in heart and skeletal muscles. Med Sci Sports Exerc 32(4):778\u2013789","journal-title":"Med Sci Sports Exerc"},{"issue":"5","key":"1978_CR49","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/01.CIR.0000023531.22727.C1","volume":"106","author":"JC Osorio","year":"2002","unstructured":"Osorio JC, Stanley WC, Linke A et al (2002) Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-\u03b1 in pacing-induced heart failure. Circulation 106(5):606\u2013612","journal-title":"Circulation"},{"issue":"3","key":"1978_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3390\/ph16030391","volume":"16","author":"K Agostinucci","year":"2023","unstructured":"Agostinucci K, Grant MKO, Melaku W, Nair C, Zordoky BN (2023) Exposure to doxorubicin modulates the cardiac response to isoproterenol in male and female mice. Pharmaceuticals 16(3):391","journal-title":"Pharmaceuticals"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01978-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-024-01978-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-024-01978-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:37:08Z","timestamp":1738928228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-024-01978-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1978"],"URL":"https:\/\/doi.org\/10.1007\/s11307-024-01978-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4876095\/v1","asserted-by":"object"}]},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study followed all applicable institutional and\/or national guidelines for the care and use of animals and approved by the Institutional Animal Care and Use Committee at Weill Cornell Medicine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare that they have no conflict of interest with regard to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}